Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity

In developing its osteoporosis drug Evenity more than a decade ago, it is alleged in court documents that Amgen discussed forming a potential partnership with a small company from Kansas.

Those discussions never amounted to a deal. Now, 11 years later, the Kansas company is suing Amgen for patent infringement.